Search clinical trials for: camrelizumab

Total 417 results

Beijing Tongren Hospital

Recruiting

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

T-lymphoblastic Lymphoma | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Fujian Medical University

Recruiting

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Hutchmed

Not yet recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Yongyi Zeng

Not yet recruiting

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Hepatocellular Carcinoma
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Borderline Resectable Pancreatic Cancer

China
Shanghai Shengdi Pharmaceutical Co., Ltd

Not yet recruiting

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Non-squamous Non-small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Lenvatinib | Hepatic Arterial Infusion Chemotherapy

China
Jinling Hospital, China
Jiangsu Synthgene Biotechnology Co.Ltd.

Recruiting

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy

Breast Neoplasms

China
Harbin Medical University

Not yet recruiting

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Rectal Cancer
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Cervical Cancer | Fertility Preservation | Neoadjuvant Chemoimmunotherapy

China
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Cervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant Chemoimmunotherapy

China
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Cervical Cancer | Locally Advanced Cervical Cancer | Concurrent Chemoradiotherapy | Neoadjuvant Chemoimmunotherapy

China
Meng Chao Hepatobiliary Hospital of Fujian Medical...

Not yet recruiting

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Hepatocellular Carcinoma

China
Tongji University
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Camrelizumab
Fudan University

Not yet recruiting

PD-1 Inhibitor Plus Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer (PTCA199-11)

Pancreatic Adenocarcinoma
Shandong Cancer Hospital and Institute

Recruiting

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant Therapy | Resectable Lung Non-Small Cell Carcinoma | IMMUNOTHERAPY | Biomarkers / Blood

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma

China
Henan Cancer Hospital
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Esophageal Carcinoma | Lung Cancer, Nonsmall Cell

China
Peking University Cancer Hospital & Institute
Beijing Nanjiao Cancer Hospital

Recruiting

Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

Rectal Cancer

China
Peking Union Medical College Hospital

Recruiting

Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer (NITDC)

Colon Cancer | Immunotherapy | Mismatch Repair Deficiency

China
Fudan University

Not yet recruiting

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer (PTCA199-8)

Pancreatic Cancer
yue junhan

Recruiting

Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer (FOBECAMS)

Colorectal Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Chemotherapy Effect | BCLC Stage C Hepatocellular Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma (Siewert II-III)

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

Unresectable/Metastatic Colorectal Cancer

China
Xuanwu Hospital, Beijing

Recruiting

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Chordoma | Chemotherapy Effect

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Not yet recruiting

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Primary Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Breast Neoplasms

China
West China Hospital

Recruiting

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...
The First Affiliated Hospital with Nanjing Medical University; Fujian Cancer... and other collaborators

Recruiting

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Esophageal Neoplasms

China
Ruijin Hospital

Recruiting

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) (PRIMA)

Sarcoma | Sarcoma,Soft Tissue | Sarcoma of Bone

China
Sun Yat-sen University

Not yet recruiting

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Camrelizumab | Lenvatinib

China
Chongqing University Cancer Hospital

Not yet recruiting

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

PARP Inhibitor for Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Fudan University

Recruiting

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

China
Jun Guo

Not yet recruiting

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Melanoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Breast Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Fujian Cancer Hospital

Recruiting

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Carcinoma | Cervix Carcinoma

China
Sun Yat-sen University

Recruiting

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Wan-Guang Zhang

Recruiting

A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC (CCGLC-010)

Macrotrabecular Massive Hepatocellular Carcinoma

China
CrystalGenomics, Inc.

Recruiting

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non Squamous Non Small Cell Lung Cancer

Korea, Republic of
Nanfang Hospital of Southern Medical University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients (PANORAMA)

Chemotherapy | Immunotherapy

China
Fujian Medical University Union Hospital

Not yet recruiting

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Chemotherapy | Radiation Therapy

China
Amsterdam UMC, location VUmc
Medtronic

Not yet recruiting

Predictive Factors for Succes of ITB in CP

Cerebral Palsy | Intrathecal Baclofen

Search clinical trials for: camrelizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations